{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:04:46Z","timestamp":1791353086675,"version":"4.3.1"},"reference-count":169,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Mantle cell lymphoma is a clinically heterogeneous disease occurring within a heterogeneous patient population, highlighting a need for personalized therapy to ensure optimal outcomes. It is therefore critical to understand the benefits and risks associated with both intensive and deintensified approaches. In the following review we provide a therapeutic roadmap to strategically guide treatment for newly diagnosed and relapsed\/refractory patients highlighting pivotal and recently published results involving known and novel therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T23:25:27Z","timestamp":1491521127000},"page":"99-115","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Mantle Cell Lymphoma"],"prefix":"10.4103","volume":"10","author":[{"given":"Jose D.","family":"Sandoval-Sus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo M.","family":"Sotomayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.02.003_b0005","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0010","series-title":"WHO classification of tumors of the haematopietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.hemonc.2017.02.003_b0015","first-page":"3909","article-title":"The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","author":"A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0020","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin\u2019s lymphomas, version 4.2014","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.hemonc.2017.02.003_b0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0030","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2012.760041","article-title":"An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA","volume":"54","author":"Aschebrook-Kilfoy","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.02.003_b0035","first-page":"314","article-title":"Familial lymphoid neoplasms in patients with mantle cell lymphoma","volume":"89","author":"Tort","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.02.003_b0040","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1182\/blood-2007-08-109611","article-title":"Borrelia infection and risk of non-Hodgkin lymphoma","volume":"111","author":"Schollkopf","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0045","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2006-06-031948","article-title":"Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph)","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/aje\/kwp383","article-title":"Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium","volume":"171","author":"Skibola","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jncimonographs\/lgu007","article-title":"Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph non-Hodgkin lymphoma subtypes Project","volume":"2014","author":"Smedby","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.hemonc.2017.02.003_b0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/107327481201900307","article-title":"Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches","volume":"19","author":"Shah","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.hemonc.2017.02.003_b0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0070","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3109\/10428194.2015.1026902","article-title":"Clinicopathologic features and management of blastoid variant of mantle cell lymphoma","volume":"56","author":"Shrestha","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.02.003_b0075","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1309\/R94MAFJY5EA4A8C3","article-title":"CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease","volume":"130","author":"Kelemen","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1309\/TE56-A43X-29TT-5H8G","article-title":"CD5- mantle cell lymphoma","volume":"118","author":"Liu","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2559.2008.03060.x","article-title":"Mantle cell lymphoma with aberrant expression of CD10","volume":"53","author":"Zanetto","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.hemonc.2017.02.003_b0095","first-page":"1456","article-title":"Bcl-2 protein in centrocytic lymphoma; a paraffin section study","volume":"7","author":"Swerdlow","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.02.003_b0100","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1309\/TYE7K2CQMQ707FRT","article-title":"Antibody selection in immunohistochemical detection of cyclin D1 in mantle cell lymphoma","volume":"124","author":"Torlakovic","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/ajcp\/103.6.756","article-title":"Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry","volume":"103","author":"Zukerberg","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.767","article-title":"Update on the molecular biology of mantle cell lymphoma","volume":"24","author":"Bertoni","year":"2006","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","article-title":"Mantle cell lymphoma: the promise of new treatment options","volume":"80","author":"Goy","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0125","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","article-title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization","volume":"154","author":"Li","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/modpathol.3880556","article-title":"A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas","volume":"15","author":"Belaud-Rotureau","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0135","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","article-title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma","volume":"121","author":"Vegliante","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0140","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hemonc.2017.02.003_b0150","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.02.003_b0155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0160","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","article-title":"Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study","volume":"30","author":"Salar","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.seminhematol.2011.03.010","article-title":"Is there a role for \u201cwatch and wait\u201d in patients with mantle cell lymphoma?","volume":"48","author":"Martin","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0170","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0175","unstructured":"Shah BD TJ, MD, Sotomayor EM. Mantle cell lymphoma: not always agressive, not always resistant. In: Jonathan W, Pine J, editors. PPO updates, principles & practice of oncology, Vincent T Devita, Jr, Samuel Hellman, Steven A Rosenberg (Eds). 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013:1\u201315."},{"key":"10.1016\/j.hemonc.2017.02.003_b0180","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/cncr.27898","article-title":"Using primary site as a predictor of survival in mantle cell lymphoma","volume":"119","author":"Ambinder","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"key":"10.1016\/j.hemonc.2017.02.003_b0190","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1349-7006.2011.01988.x","article-title":"Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index","volume":"102","author":"Kimura","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.hemonc.2017.02.003_b0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/his.12009","article-title":"Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression","volume":"62","author":"Vogt","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.hemonc.2017.02.003_b0200","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2559.2007.02906.x","article-title":"In-situ mantle cell lymphoma \u2013 a report of two cases","volume":"52","author":"Aqel","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.hemonc.2017.02.003_b0205","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1200\/JCO.2010.29.8992","article-title":"Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor","volume":"28","author":"Christian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0210","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/modpathol.2012.117","article-title":"Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues","volume":"25","author":"Adam","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0215","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.2011.052621","article-title":"In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior","volume":"97","author":"Carvajal-Cuenca","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.02.003_b0220","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0225","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvement in mantle cell lymphoma","volume":"19","author":"Ferrer","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0230","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0235","first-page":"987","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","author":"A predictive model for aggressive non-Hodgkin's lymphoma","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.02.003_b0240","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0245","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0250","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0255","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0260","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1158\/1078-0432.CCR-14-0836","article-title":"New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?","volume":"20","author":"Dreyling","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hemonc.2017.02.003_b0265","doi-asserted-by":"crossref","unstructured":"Patrick T. Griffin JCC, Celeste M. Bello, Lubomir Sokol, Paul A. Chervenick, Ernesto Ayala, Jianguo Tao, Eduardo M. Sotomayor, Bijal D. Shah. Increased treatment intensity is not associated with a survival benefit in patients with low and intermediate risk Mantle Cell Lymphoma, a retrospective analysis. In: 56th American Society of Hematology Annual Meeting; 2014 December 6, 2015; San Francisco, CA. p. 4424.","DOI":"10.1182\/blood.V124.21.4424.4424"},{"key":"10.1016\/j.hemonc.2017.02.003_b0270","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3324\/haematol.2009.021113","article-title":"Validation, revision and extension of the Mantle Cell Lymphoma international prognostic index in a population-based setting","volume":"95","author":"van de Schans","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.02.003_b0275","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0280","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0285","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0290","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0295","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0300","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1002\/ajh.23996","article-title":"Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma","volume":"90","author":"Hosein","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0305","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0310","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0315","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0320","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0325","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0330","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.02.003_b0335","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11899-016-0324-3","article-title":"Which patients with mantle cell lymphoma do not need aggressive therapy","volume":"11","author":"Ruan","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.hemonc.2017.02.003_b0340","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0345","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3322\/caac.21255","article-title":"Retreatment with rituximab offers a similar survival benefit as maintenance therapy in patients with low tumor burden follicular lymphoma","volume":"65","author":"Barton","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hemonc.2017.02.003_b0355","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-0609.2002.00551.x","article-title":"The splenic form of mantle cell lymphoma","volume":"68","author":"Angelopoulou","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0360","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1046\/j.1365-2141.2002.03716.x","article-title":"Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia","volume":"118","author":"Ruchlemer","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0365","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<850::AID-CNCR22>3.0.CO;2-Z","article-title":"Mantle cell lymphoma in leukemic phase: characterization of its broad cytologic spectrum with emphasis on the importance of distinction from other chronic lymphoproliferative disorders","volume":"86","author":"Wong","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0370","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1309\/JQMR-323G-71Y9-M7MB","article-title":"Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities","volume":"116","author":"Onciu","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0375","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.3880448","article-title":"Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases","volume":"14","author":"Schlette","year":"2001","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0380","first-page":"1141","article-title":"P53 and mdm2 in mantle cell lymphoma in leukemic phase","volume":"87","author":"Solenthaler","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.02.003_b0385","unstructured":"Ruan J, Martin P, Shah BD, Schuster SJ, Smith SM, Furman RR, et al. Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for Mantle Cell Lymphoma: A multi-center phase II study report. In: 56th ASH meeting and exposition 2014 December 8, 2014; San Francisco, CA."},{"key":"10.1016\/j.hemonc.2017.02.003_b0390","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/10428190410001723331","article-title":"The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients","volume":"45","author":"Matutes","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.02.003_b0395","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the princess margaret hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.02.003_b0400","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/10428194.2012.731053","article-title":"Limited-stage mantle cell lymphoma: not so different from advanced-stage","volume":"54","author":"Martin","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.02.003_b0405","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0410","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hemonc.2017.02.003_b0415","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0420","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hemonc.2017.02.003_b0425","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0430","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0435","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0440","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hemonc.2017.02.003_b0445","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0450","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0455","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.hemonc.2017.02.003_b0460","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0465","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2000.18.4.773","article-title":"Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0470","doi-asserted-by":"crossref","unstructured":"Rule S, Smith P, Johnson PW, Bolam S, Gambell J, Hillmen P, et al. The addition of rituximab to fludarabine and cyclophosphamide (fc) improves overall survival in newly diagnosed Mantle cell lymphoma (MCL): Results of the randomised UK National Cancer Research Institute (NCRI) Trial. In: 53th American Society of Hematology Annual Meeting and Exposition; 2011; San Diego, CA.","DOI":"10.1182\/blood.V118.21.440.440"},{"key":"10.1016\/j.hemonc.2017.02.003_b0475","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.02.003_b0480","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0485","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0490","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.2011-0341","article-title":"Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside","volume":"17","author":"Mato","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.hemonc.2017.02.003_b0495","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.02.003_b0500","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern cooperative oncology group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0505","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2165\/11205860-000000000-00000","article-title":"Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"70","author":"Garnock-Jones","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.hemonc.2017.02.003_b0510","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0515","doi-asserted-by":"crossref","unstructured":"Czuczman MS, Lamonica D, Gaylor SK, Bush L, Nadolny P, Colborn D, et al Open-label bendamustine combined with rituximab for treatment of relapsed\/refractory MantleCell Lymphoma: efficacy and safety findings. In: 54th ASH Annual Meeting and Exposition; 2012; Atlanta, GA.","DOI":"10.1182\/blood.V120.21.3662.3662"},{"key":"10.1016\/j.hemonc.2017.02.003_b0520","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2017.02.003_b0525","unstructured":"Rummel MJ, Knauf W, Goerner M, Soeling U, Lange E, Hertenstein B, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). 2016 ASCO Annual Meeting 2016; Chicago, IL. p. suppl; abstr 7503."},{"key":"10.1016\/j.hemonc.2017.02.003_b0530","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0535","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0540","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3109\/10428194.2011.600488","article-title":"Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network","volume":"52","author":"Dreyling","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2017.02.003_b0545","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0550","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0555","unstructured":"Gressin R, Callanan M, Daguindau N, Tempescul A, Carras S, Moles MP, et al. Frontline therapy with the Ribvd regimen elicits high clinical and molecular response rates and long PFS in elderly patients Mantle Cell Lymphoma (MCL); Final results of a prospective phase II trial by the lysa group. In: 56th ASH annual meeting and exposition; 2014 December 7, 2014; San Francisco, CA."},{"key":"10.1016\/j.hemonc.2017.02.003_b0560","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","article-title":"A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0565","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0570","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.02.003_b0575","doi-asserted-by":"crossref","unstructured":"Vidal L G-GA, Dreyling M, Ghielmini M, Unterhalt M, Raanani P, Shpilberg O, et al. Rituximab Maintenance (MR) for patients with Mantle Cell Lymphoma (MCL) \u2013 a systematic review and meta-analysis of randomized controlled trials (RCTs). In: 56th ASH Annual Meeting and Exposition; 2014 December 8, 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.4466.4466"},{"key":"10.1016\/j.hemonc.2017.02.003_b0580","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1991.9.3.423","article-title":"Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation","volume":"9","author":"Press","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0585","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.02.003_b0590","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0595","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0600","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0605","unstructured":"Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). In: 54th ASH Annual Meeting and Exposition; 2012 December 9, 2012; Atlanta, Georgia."},{"key":"10.1016\/j.hemonc.2017.02.003_b0610","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2017.02.003_b0615","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with Mantle Cell Lymphoma: Final results of the randomized phase 3 LyMa Trial of the Lysa\/Goelams Group. In: 58th ASH Annual Meeting 2016; San Diego, CA. p. 145.","DOI":"10.1182\/blood.V128.22.145.145"},{"key":"10.1016\/j.hemonc.2017.02.003_b0620","doi-asserted-by":"crossref","unstructured":"Kolstad A, Pedersen LB, Eskelund CW, Husby S, Gr\u00f8nb\u00e6k K, Jerkeman MLU, et al. Molecular monitoring and tailored strategy with pre-emptive rituximab treatment for molecular relapse; results from the nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with median follow-up of 8.5 Years. In: 58th ASH annual meeting; 2016; San Diego, CA. p. 146.","DOI":"10.1016\/j.bbmt.2016.12.634"},{"key":"10.1016\/j.hemonc.2017.02.003_b0625","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.02.003_b0630","unstructured":"Pott C, Macintyre E, Delfau-Larue M-H, Ribrag V, Unterhalt M, Kneba M, et al. MRD Eradication should be the therapeutic goal in Mantle Cell Lymphoma and may enable tailored treatment approaches: results of the intergroup trials of the European MCL Network. In: 56th ASH Annual Meeting and Exposicion; 2014 December 7, 2014; San Francisco, CA."},{"key":"10.1016\/j.hemonc.2017.02.003_b0635","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","article-title":"Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database","volume":"119","author":"LaCasce","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0640","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0645","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/1078-0432.CCR-15-0488","article-title":"Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice","volume":"21","author":"Avivi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hemonc.2017.02.003_b0650","doi-asserted-by":"crossref","unstructured":"Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent, or Mantle Cell Lymphomas \u2013 8-Year Follow-up results of the randomized phase III Study NHL 2\u20132003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). In: 56 ASH Meeting and Exposition; 2014 December 7, 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.145.145"},{"key":"10.1016\/j.hemonc.2017.02.003_b0655","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0660","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0665","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0670","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0675","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0680","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0685","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bjh.12945","article-title":"Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies","volume":"166","author":"Eyre","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0690","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0695","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the north central cancer treatment group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0700","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0705","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2015.60","article-title":"Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma","volume":"29","author":"Hess","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.02.003_b0710","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.02.003_b0715","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0720","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/leu.2015.215","article-title":"Radioimmunotherapy in relapsed\/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial","volume":"30","author":"Ferrero","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.02.003_b0725","first-page":"979","article-title":"A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia","volume":"11","author":"Tucker","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.hemonc.2017.02.003_b0730","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","article-title":"Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician","volume":"32","author":"Byrd","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0735","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.hemonc.2017.02.003_b0740","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0745","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.hemonc.2017.02.003_b0750","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0755","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1475-2867-14-32","article-title":"Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment","volume":"14","author":"Zheng","year":"2014","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.hemonc.2017.02.003_b0760","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Zhang","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0765","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0770","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0775","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0780","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Post-ibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0785","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0790","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0795","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0800","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.02.003_b0805","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.02.003_b0810","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0815","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0820","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biology of blood and marrow transplantation","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.02.003_b0825","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0830","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.02.003_b0835","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/CJI.0b013e3181adaff1","article-title":"Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma","volume":"32","author":"Mihara","year":"2009","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"10.1016\/j.hemonc.2017.02.003_b0840","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.hemonc.2017.02.003_b0845","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ajh.24238","article-title":"CAR T-cells merge into the fast lane of cancer care","volume":"91","author":"Frey","year":"2016","journal-title":"Am J Hematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201710030-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:06Z","timestamp":1787838546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201710030-00001"}},"subtitle":["Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine"],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":169,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.02.003","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}